Loading content

Ms Claire Bewshea

Exeter IBD and Pharmacogenetics Project Manager

01392 406850

RILD Building L3/L06C

I am currently  working with Dr Tariq Ahmad, Consultant Gastroenterologist, Royal Devon and Exeter Hospital in delivering multi- centre NIHR  research projects in the field of Inflammatory Bowel Disease (IBD).

I graduated from University of Southampton in 1997 with a BSc (Hons) in  Pharmacology and Physiology. During my  time at Southampton  I also completed a industry placement with Bayer plc, and then went to work and train as a Clinical Research Scientist.   I then relocated to the South West and went on to work for  AstraZeneca until  2006.

From 2008 until 2011 I worked for NHS Devon as a Research and Clinical Trials Manager.

I have been working with Dr Tariq Ahmad since March 2011.

 

 

 

 

Qualifications

BSc (Hons) Pharmacology and Physiology 1997

Clinical Research Scientist 1998

 

Career

Boots 1988-1992

Bayer plc 1995-2002

Astrazeneca 2002-2006

NHS Devon 2008-2011

 

 

 

Links

Research

Research interests

Inflammatory Bowel Disease Genetics of drug side effects anti-TNF response.

Research projects

5ASA - 5- AMINOSALICYLATE INDUCED NEPHROTOXICITY IN IBD PRED4 - Predicting Serious Drug Side Effects in Gastroenterology PANTS- Personalising Anti-TNF Therapy in Crohns Disease.

Research networks

National Institute for Health Research Royal Devon and Exeter Hospital Exeter CRF RD&E Blood Sciences British Society of Gastroenterology Crohn's and Colitis UK International Serious Adverse Event Consortium IBD GENETIC Consortium International IBD Genetics Consortium

Key publications | Publications by category | Publications by year

Publications by category


Journal articles

Carrieri D, Bewshea C, Walker G, Ahmad T, Bowen W, Hall A, Kelly SE (In Press). Ethical issues and best practice in clinically based genomic research: Exeter Stakeholders Meeting Report. Journal of Medical Ethics Full text.
Heap GA, So K, Weedon M, Edney N, Bewshea C, Singh A, Annese V, Beckly J, Buurman D, Chaudhary R, et al (2016). Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. J Crohns Colitis, 10(2), 149-158. Abstract.  Author URL.
Perry M, Bewshea C, Brown R, So K, Ahmad T, McDonald T (2015). Infliximab and adalimumab are stable in whole blood clotted samples for seven days at room temperature. Ann Clin Biochem, 52(Pt 6), 672-674. Abstract.  Author URL.
Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell JB, Vivian JP, So K, Dubois PC, Andrews JM, et al (2014). HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nature Genetics, 46(10), 1131-1134. Abstract.
Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell JB, Vivian JP, So K, Dubois PC, Andrews JM, et al (2014). HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet, 46(10), 1131-1134. Abstract.  Author URL.

Conferences

Walker G, Heap G, Bewshea C, Ahmad T, Irving P, Goodhand J (2016). ANTI-TNF PATIENT TREATMENT PREFERENCES: DATA FROM THE PANTS STUDY.  Author URL.
Heap G, Bewshea C, Singh A, Weedon M, Goldstein J, Ebney N, Mulgrew C, D'Souza R, Oram R, Orchard T, et al (2014). A genome wide association study identifying association of the MHC region with 5-aminosalicylate (5-ASA) induced nephrotoxicity in inflammatory bowel disease.  Author URL.
Heap GA, Singh A, Bewshea C, Weedon MN, Cole A, Creed T, Greig E, Irving P, Lindsay J, Mawdsley J, et al (2014). THIOPURINE INDUCED PANCREATITIS IN INFLAMMATORY BOWEL DISEASE: CLINICAL FEATURES AND GENETIC DETERMINANTS.  Author URL.
Heap GA, Singh A, Bewshea CM, Weedon M, Dubois P, Andrews JM, Annese V, Bampton PA, Bell S, Cole A, et al (2014). Thiopurine Induced Pancreatitis in Inflammatory Bowel Disease: Clinical Features and Genetic Determinants.  Author URL.
So K, Bewshea C, Heap GA, Muller AF, Daneshmend TK, Hart AL, Orchard TR, Irving PM, Russell RK, Wilson DC, et al (2013). 5-AMINOSALICYLATE (5-ASA) INDUCED NEPHROTOXICITY IN INFLAMMATORY BOWEL DISEASE.  Author URL.
So K, Bewshea CM, Heap GA, Muller AF, Delaney MP, Daneshmend TK, Hart AL, Orchard TR, Irving PM, D'Souza R, et al (2013). 5-Aminosalicylate (5-ASA) Induced Nephrotoxicity in Inflammatory Bowel Disease.  Author URL.

Publications by year


In Press

Carrieri D, Bewshea C, Walker G, Ahmad T, Bowen W, Hall A, Kelly SE (In Press). Ethical issues and best practice in clinically based genomic research: Exeter Stakeholders Meeting Report. Journal of Medical Ethics Full text.

2016

Walker G, Heap G, Bewshea C, Ahmad T, Irving P, Goodhand J (2016). ANTI-TNF PATIENT TREATMENT PREFERENCES: DATA FROM THE PANTS STUDY.  Author URL.
Heap GA, So K, Weedon M, Edney N, Bewshea C, Singh A, Annese V, Beckly J, Buurman D, Chaudhary R, et al (2016). Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. J Crohns Colitis, 10(2), 149-158. Abstract.  Author URL.

2015

Perry M, Bewshea C, Brown R, So K, Ahmad T, McDonald T (2015). Infliximab and adalimumab are stable in whole blood clotted samples for seven days at room temperature. Ann Clin Biochem, 52(Pt 6), 672-674. Abstract.  Author URL.

2014

Heap G, Bewshea C, Singh A, Weedon M, Goldstein J, Ebney N, Mulgrew C, D'Souza R, Oram R, Orchard T, et al (2014). A genome wide association study identifying association of the MHC region with 5-aminosalicylate (5-ASA) induced nephrotoxicity in inflammatory bowel disease.  Author URL.
Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell JB, Vivian JP, So K, Dubois PC, Andrews JM, et al (2014). HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nature Genetics, 46(10), 1131-1134. Abstract.
Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell JB, Vivian JP, So K, Dubois PC, Andrews JM, et al (2014). HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet, 46(10), 1131-1134. Abstract.  Author URL.
Heap GA, Singh A, Bewshea C, Weedon MN, Cole A, Creed T, Greig E, Irving P, Lindsay J, Mawdsley J, et al (2014). THIOPURINE INDUCED PANCREATITIS IN INFLAMMATORY BOWEL DISEASE: CLINICAL FEATURES AND GENETIC DETERMINANTS.  Author URL.
Heap GA, Singh A, Bewshea CM, Weedon M, Dubois P, Andrews JM, Annese V, Bampton PA, Bell S, Cole A, et al (2014). Thiopurine Induced Pancreatitis in Inflammatory Bowel Disease: Clinical Features and Genetic Determinants.  Author URL.

2013

So K, Bewshea C, Heap GA, Muller AF, Daneshmend TK, Hart AL, Orchard TR, Irving PM, Russell RK, Wilson DC, et al (2013). 5-AMINOSALICYLATE (5-ASA) INDUCED NEPHROTOXICITY IN INFLAMMATORY BOWEL DISEASE.  Author URL.
So K, Bewshea CM, Heap GA, Muller AF, Delaney MP, Daneshmend TK, Hart AL, Orchard TR, Irving PM, D'Souza R, et al (2013). 5-Aminosalicylate (5-ASA) Induced Nephrotoxicity in Inflammatory Bowel Disease.  Author URL.

Pharmacology

Inflammatory Bowel Disease.

 

Back | Edit Profile